Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EVOLUTION OF THROMBOLYTIC THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION

https://doi.org/10.20996/1819-6446-2014-10-5-554-558

Full Text:

Abstract

History of thrombolytic therapy is shortly reflected, main trials of various thrombolytics in acute ST-segment elevation myocardial infarction (STEMI) are analyzed. Perspectives of modern thrombolytic therapy in patients with STEMI are discussed.

About the Authors

P. G. Kesov
Regional Cardiology Clinic of Tyumen Regional Hospital №1
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia


O. M. Reytblat
Regional Cardiology Clinic of Tyumen Regional Hospital №1
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia


Z. M. Safiullina
Tyumen State Medical Academy
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia


S. V. Shalaev
Regional Cardiology Clinic of Tyumen Regional Hospital №1, Tyumen State Medical Academy
Russian Federation

Odesskaya ul. 46A, Tyumen, 625023 Russia

Odesskaya ul. 46A, Tyumen, 625023 Russia



References

1. Chazov E.I., Ruda M.J. Development of the main directions in the treatment of patients with myocardial infarction in the last 25 years. Cardiology 1989; (11): 11-5. Russian (Чазов Е.И., Руда М.Я. Развитие основных направлений в лечении больных инфарктом миокарда за последние 25 лет. Кардиология 1989;(11): 11-5).

2. Rentrop K.P., Blanke H., Karsch K.R, et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979; 2: 354-63.

3. De Wood M.A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.

4. Schroder R., Biamino G., von Leitner E., et al. Intravenose Streptokinase-Infusion beim akutem Myokardinfarkt. Dtsch Med Wschr 1981; 106: 294-7.

5. Gruppo Italiano per lo Studio della Streptochinasi nell’infarcto myocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401.

6. ISIS-2 (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-60.

7. Panchenko E.P., Dobrovolsky A.V. Thrombosis in cardiology. Moscow: SportsandCulture; 1999. Russian (ПанченкоЕ.П., ДобровольскийА.В. Тромбозывкардиологии. М.: Спортикультура; 1999).

8. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.

9. Wilcox RG, von der Lippe G, Olsson CG et al. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis. Lancet 1990;335(8699):1175-8.

10. Third International Study of Infarct Survival Collaborative Group (ISIS 3). A randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet1992; 339: 753-70.

11. Sabadash E. Metalize® – a new era of thrombolytic therapy for acute myocardial infarction. Health of Ukraine, 2004; (98): 4. Ukrainian(Сабадаш Э.Метализе® – новая эра тромболитической терапии острого инфаркта миокарда. Здоровье Украины 2004;(98):4).

12. Tsikouris J.P., Tsikouris A.P. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 2001 ;21:207-17.

13. Vakili B.A., Kaplan R., Brown D.L. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation 2001; 104: 2171-6.

14. Collen D., Stassen J.M., Yasuda T et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1 -resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994;72:98-104.

15. Cannon C.P, McCabe C.H., Gibson C.M. et al. TN K-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-6.

16. Cannon C.P, Gibson C.M., McCabe C.H. et al. TN K-tissue plasminogen activator compared with frontloaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-14.

17. Van de Werf F., Cannon C.P, Luyten A. et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT- 1 trial. The ASSENT-1 Investigators. Am Heart J 1999;137:786-91.

18. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-22.

19. Van de Werf F, Barron H.V, Armstrong P.W. et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin- specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253-61.

20. Melandri G., Vagnarelli F, Calabrese D. et al. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vascular Health and Risk Management 2009: 5; 249-56.

21. Sinnaeve P.A., Alexander J.B., Belmans A.C. et al. One-year follow-up of the ASSENT-2 trial: A double-blind, randomized comparison of single- bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST- elevation acute myocardial infarction. Am Heart J 2003;146:27-32.

22. Wallentin L., Goldstein P., Armstrong P. et al. Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Acute Myocardial Infarction. Circulation 2003;108: 135-42.

23. Lamfers E., Hooghoudt T., Hertzberger D. et al. Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients’ characteristics, and prognosis. Heart 2003; 89(5): 496-501.

24. Morrison L.J., Verbeek P.R., McDonald A.C. et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283: 2686-92.

25. Van Domburg R.T., Kappetein A.P., Bogers Ad J.J. The clinical outcome after coronary bypass surgery: a 30-year follow-app study. Eur Heart J 2009; 30(4): 453-8.

26. Armstrong PW, Gershlick A, Goldstein P, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010;160(1):30.e1-35.e1.

27. Armstrong PW, Gershlick AH, Goldstein P et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;368(15):1379-87.

28. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20): 2569-619.


For citation:


Kesov P.G., Reytblat O.M., Safiullina Z.M., Shalaev S.V. EVOLUTION OF THROMBOLYTIC THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION. Rational Pharmacotherapy in Cardiology. 2014;10(5):554-558. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-554-558

Views: 382


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)